Compare Alcon AG (ALC) vs Angi Inc (ANGI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Angi Inc — how do they compare? Alcon AG trades at $66.84 (market cap $32.69B), while Angi Inc trades at $6.13 (market cap $260.08M). The key difference: Alcon AG is far larger — about 125.7× Angi Inc's market cap, and Alcon AG pays a 0.54% dividend while Angi Inc pays none. Which is the better fit depends on your goals.
| ALC | ANGI | |
|---|---|---|
Market Cap | $32.69B | $260.08M |
Sector | Health | Media |
52-Week High | $92.22 | $18.90 |
52-Week Low | $62.02 | $4.78 |
Enterprise Value | $36.28B | $486.89M |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
ANGI trades at $6.44, up 6.27% today, with a bullish technical signal from moving averages but mixed oscillators. Revenue declined to $1.03B in 2025, though net income improved to $43.83M. Valuation ratios appear low with P/E of 14.86 and P/S of 0.27. Recent news highlights an AI strategy pivot and multiple law firm fraud investigations, creating uncertainty.
The stock offers potential upside to the $9.20 consensus price target, but risks include declining revenue, negative cash flows, and legal scrutiny. Analyst sentiment is cautious with 62.97% hold ratings. Execution of the AI transition and resolution of legal issues are critical for future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Angi Inc
Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. It has two geographical segments namely North America (the United States and Canada), which primarily includes the operations HomeAdvisor, Angie's List, Handy, mHelpDesk, HomeStars, and Fixd Repair
Read more on ANGI →
